BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

Core Insights - BioAtla, Inc. presented promising clinical data for its antibody drug conjugate mecbotamab vedotin and anti-CTLA-4 antibody evalstotug during a virtual R&D Day, highlighting their potential in treating solid tumors, particularly in patients with KRAS mutations [1][2][3] Group 1: Mecbotamab Vedotin - Mecbotamab vedotin (CAB-AXL-ADC) shows clinical benefit in non-small cell lung cancer (NSCLC) patients with mutant KRAS variants, with confirmed responses observed in heavily pretreated patients [2][3] - AXL expression of ≥1% is correlated with clinical benefit in patients who have undergone a median of three prior lines of therapy [3] - Initial clinical benefits were noted across various KRAS mutation variants, including G12A, G12C, and G12V, supporting a trend towards improved overall survival compared to KRAS wildtype [3] Group 2: Evalstotug - Evalstotug (CAB-CTLA-4 antibody) demonstrates promising anti-tumor activity as a monotherapy and in combination with PD-1, with a low incidence of immune-related adverse events [1][2] - In a Phase 1/2 trial, 3 out of 8 patients at the 350mg dose level showed confirmed responses, with patients receiving a mean of 7.2 doses compared to lower averages for other CTLA-4 inhibitors [3][4] - Only 2 out of 21 patients experienced grade 3 immune-related adverse events, indicating a manageable safety profile [3][4] Group 3: Company Overview - BioAtla is a clinical-stage biotechnology company focused on developing conditionally active biologic (CAB) therapeutics for solid tumors, with operations in San Diego and Beijing [9][10] - The company has two first-in-class CAB programs in Phase 2 clinical testing: mecbotamab vedotin and ozuriftamab vedotin, along with a CAB-CTLA-4 antibody designed to reduce systemic toxicity [10]